Post-hoc analysis evaluating safety of atogepant in ADVANCE & open-label extension participants with cardiovascular risk factors

被引：0

作者：

Blumenfeld, A. M. ^{[1
,2
]}

Pavlovic, J. M. ^{[3
]}

Harriott, A. ^{[4
]}

Best, P. J. ^{[5
]}

Monteith, T. ^{[6
]}

Ferreira, R. ^{[7
]}

Ma, J. ^{[7
]}

Smith, J. H. ^{[7
]}

Dabruzzo, B. L. ^{[7
,8
]}

Nahas, S. J. ^{[9
]}

机构：

[1] Headache Ctr Southern Calif, Carlsbad, CA USA

[2] Headache Ctr Southern Calif, San Diego, CA USA

[3] Albert Einstein Coll Med, Montefiore Headache Ctr, Bronx, NY 10467 USA

[4] Massachusetts Gen Hosp, Boston, MA 02114 USA

[5] Mayo Clin, Rochester, MN USA

[6] Univ Miami, Miami, FL USA

[7] AbbVie Inc, Madison, NJ USA

[8] AbbVie Inc, Frederick, MD USA

[9] Thomas Jefferson Univ, Philadelphia, PA 19107 USA

来源：

HEADACHE | 2022年 / 62卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P-137

引用

页码：119 / 119

页数：1

共 50 条

[1] Post-hoc Analysis Evaluating Safety of Atogepant in ADVANCE & Open-Label Extension Participants with Cardiovascular Risk Factors
Blumenfeld, A.
Pavlovic, J.
Harriott, A.
Best, P.
Montheith, T.
Ferreira, R. De Abreu
Ma, J.
Smith, J.
Dabruzzo, B.
Nahas, S.
[J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
[2] Post Hoc Analysis of PROGRESS: Evaluating the Safety of Atogepant in Participants With Chronic Migraine and Cardiovascular Risk Factors
Best, Patricia
Harriott, Andrea
Monteith, Teshamae
Tassorelli, Cristina
Nahas, Stephanie
Liu, Yingyi
Dabruzzo, Brett
Ferreira, Rosa De Abreu
Smith, Jonathan H.
[J]. NEUROLOGY, 2023, 100 (17)
[3] Post hoc analysis of progress: Evaluating the safety of atogepant in participants with chronic migraine and cardiovascular risk factors
Best, Patricia
Harriott, Andrea
Monteith, Teshamae
Tassorelli, Cristina
Nahas, Stephanie
Davidovic, Goran
Liu, Yingyi
Dabruzzo, Brett
Ferreira, Rosa De Abreu
Smith, Jonathan
[J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
[4] Number of seizure-free days with adjunctive cenobamate: post-hoc analysis of an open-label extension study
Brandt, C.
Fabo, D.
Milovanovic, M.
Alvarez-Baron, E.
Thangavelu, K.
Milanov, I.
[J]. EPILEPSIA, 2023, 64 : 58 - 58
[5] Number of seizure-free days with adjunctive cenobamate: post-hoc analysis of an open-label extension study
Brandt, C.
Fabo, D.
Milovanovic, M.
Alvarez-Baron, E.
Thangavelu, K.
Milanov, I.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 171 - 171
[6] Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis
Takei, Koji
Tsuda, Kikumi
Takahashi, Fumihiro
Palumb, Joseph
[J]. AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2017, 18 : 64 - 70
[7] Benefit-Risk Assessment of Atogepant: A Post Hoc Analysis of the ADVANCE Trial
Nahas, Stephanie
Ailani, Jessica
McAllister, Peter
Singh, Rashmi Halker
Lipton, Richard B.
Ma, Julia
Gandhi, Pranav
Smith, Jonathan H.
Liu, Yingyi
Chalermpalanupap, Natty
Dabruzzo, Brett
[J]. NEUROLOGY, 2023, 100 (17)
[8] Predictors of Achievement of Response With Cenobamate: Post-hoc Subset Analysis From a Phase 3, Open-Label Safety Study
Wechsler, Robert
Vossler, David G.
Kerr, Wesley T.
Stern, Sean
Wade, Clarence T.
Rosenfeld, William E.
[J]. NEUROLOGY, 2023, 100 (17)
[9] Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post-hoc analysis of a long-term open-label study
Ishigooka, Jun
Inada, Ken
Niidome, Kazunari
Aoki, Kazuo
Kojima, Yoshitsugu
Iwashita, Shuichi
Yamada, Sakiko
[J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2021, 36 (04)
[10] Benefit-Risk Assessment of Atogepant: A Post Hoc Analysis of the ADVANCE Trial
Nahas-Geiger, S.
Ailani, J.
McAllister, P.
Halker, Singh R.
Lipton, R.
Ma, J.
Gandhi, P.
Smith, J.
Liu, Y.
Chalermpalanupap, N.
Dabruzzo, B.
[J]. HEADACHE, 2023, 63 : 118 - 119

← 1 2 3 4 5 →